Syngene International – improving access to medicines

What does the company do?

India’s leading contract research organisation (CRO), Syngene International supports R&D programmes of global innovative companies, mainly in the fields of pharmaceutical and biotech and also in other industrial sectors such as agrochemical, nutrition, animal health, specialty and performance chemicals. The company has more recently added contract manufacturing organisation (CMO) capabilities to offer clients an end-to-end continuum of services. Syngene is a 70% subsidiary of the reputable Biocon group in India.

Why do we like the investment?

The company has a role to play in improving public healthcare system by driving innovation, operational efficiency and productivity. With longer R&D development cycles and rising costs, global pharmaceutical companies have started to partner with CROs to a) increase efficiencies, b) increase speed to market and c) reduce costs. Syngene’s value proposition to clients is to offer world-class capabilities at more affordable prices. Notable collaborations include Baxter, Bristol-Myers Squibb, Amgen and Herbalife.

Syngene upholds itself to high corporate governance standards, best-in-class product quality management as certified by ISO and OHSAS and improving on their carbon footprint having now switched to the use of solar power, a source of energy that is abundant and cheap in India.

Companies selected for illustrative purposes only to demonstrate the investment management style described herein and not as an investment recommendation or indication of future performance.

In which year did we first invest?

2019

Where is their head office?

Bengaluru, India

What is their website?

www.syngeneintl.com

Read the detailed risk warning

NMPI Status

The Company currently conducts its affairs so that securities issued by New India Investment Trust PLC can be recommended by financial advisers to ordinary retail investors in accordance with the FCA’s rules in relation to non-mainstream pooled investment products (NMPIs) and intends to continue to do so for the foreseeable future.

The Company’s securities are excluded from the FCA’s restrictions which apply to non-mainstream investment products because they are securities in an investment trust.

Pre-investment Disclosure Document (PIDD)

The Alternative Investment Fund Manager Directive (“AIFMD”) requires Aberdeen Fund Managers Limited, as the alternative investment fund manager of New India Investment Trust PLC, to make available to investors certain information prior to such investors’ investment in the Company.

The AIFMD is intended to offer increased protection to investors in investment products that do not fall under the existing European Union regime for regulation of investment products known as “UCITS”.

Read the PIDD for Aberdeen New India Investment Trust PLC

Aberdeen Asset Managers Limited is authorised and regulated by the Financial Conduct Authority in the united kingdom. the information contained in this website does not constitute an offer of, or an invitation to apply for securities in any jurisdiction where such an offer or invitation is unlawful, or in which the person making such an offer is not qualified to do so. aberdeen asset managers accepts no responsibility for the content of any external web sites.

Aberdeen asset managers limited: 10 queens terrace, aberdeen, aberdeenshire, ab10 1xl company no. sc108419

Risk Warning
Risk warning
The value of investments and the income from them can go down as well as up and you may get back less than the amount invested. Please refer to the relevant Key Information Document (KID) prior to making an investment decision. Please be aware of scams that can affect investors.